Adding simvastatin to existing treatments provided substantial additional benefits for high-risk patients with a very low annual excess risk of myopathy (0.01%).

Every Sunday: the week’s new conflicts and verdict changes — and nothing else.

Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.